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Non-Celiac Gluten Sensitivity: Literature Review
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Internal Medicine, University Hospital of Palermo (P.M., A.S., A.D.), Internal Medicine, Sciacca Hospital (Agrigento ASP) and
University of Palermo (A.C.), Palermo, ITALY
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Background: A significant percentage of the general population report problems caused by wheat and/or
gluten ingestion, even though they do not have celiac disease (CD) or wheat allergy (WA), because they test
negative both for CD-specific serology and histopathology and for immunoglobulin E (IgE)-mediated assays.
Most patients report both gastrointestinal and nongastrointestinal symptoms, and all report improvement of
symptoms on a gluten-free diet. This clinical condition has been named non-celiac gluten sensitivity (NCGS).
Aim: We attempt to define the current pathogenic, clinical, and diagnostic criteria of this “new” disease, to
provide a practical view that might be useful to evaluate, diagnose, and manage NCGS patients.
Methods: We reviewed the international literature through PubMed and Medline, using the search terms “wheat
(hyper)sensitivity,” “wheat allergy,” “wheat intolerance,” “gluten (hyper)sensitivity,” and “gluten intolerance,” and
we discuss current knowledge about NCGS.
Results: It has been demonstrated that patients suffering from NCGS are a heterogeneous group, composed
of several subgroups, each characterized by different pathogenesis, clinical history, and, probably, clinical course.
NCGS diagnosis can be reached only by excluding CD and WA. Recent evidence shows that a personal history
of food allergy in infancy, coexistent atopy, positive for immunoglobulin G (IgG) antigliadin antibodies and flow
cytometric basophil activation test, with wheat and duodenal and/or ileum–colon intraepithelial and lamina propria
eosinophil counts, could be useful to identify NCGS patients.
Conclusions: Future research should aim to identify reliable biomarkers for NCGS diagnosis and to better
define the different NCGS subgroups.
Key teaching points:
• Most patients report both gastrointestinal and nongastrointestinal symptoms, and all agree that there is an improvement of
symptoms on a gluten-free diet.
• NCGS diagnosis can be reached only by excluding celiac disease and wheat allergy.
• Patients suffering from NCGS are a heterogeneous group, composed of several subgroups, each characterized by different
pathogenesis, clinical history, and, probably, clinical course.
• A personal history of food allergy in infancy, coexistent atopy, positive IgG antigliadin antibodies (AGA) and flow cytometric
basophil activation test, with wheat and duodenal and/or ileum–colon intraepithelial and lamina propria eosinophil counts, could
be useful to identify NCGS patients.
• Future research should aim to identify reliable biomarkers for NCGS diagnosis and to better define the different NCGS subgroup.
Address correspondence to: Prof. Antonio Carroccio, Internal Medicine, Sciacca Hospital, University of Palermo, Policlinico di Palermo, via del Vespro 141, Palermo 90127,
ITALY. E-mail: acarroccio@hotmail.com
Abbreviations: CD = celiac disease, WA = wheat allergy, NCGS = non-celiac gluten sensitivity, GFD = gluten-free diet, IBS = irritable bowel syndrome, HLA = human
leukocyte antigen, tTg = antitissue transglutaminase, AGA = antigliadin antibodies, EMA = endomysial antigen, DGP = deaminated gliadin peptide, Ig = immunoglobulin,
DBPCC = double-blind placebo-controlled challenge, MHC-II = major histocompatibility complex class II, FODMAPs = fructans and other fermentable oligo- and di-
monosaccharides and polyols, TCR = T-cell receptor, IELs = intraepithelial lymphocytes, IFN = interferon, IL = interleukin, Treg = T regulation, TGF-β = transforming
growth factor-beta, Tr1 = T regulatory type 1, FoxP3 = factor box protein 3, TLRs = toll-like receptors, TJs = tight junctions, OCLN = occludin, CLDNs = claudins, ZO-1
= zonula occludens-1 protein, TJP-1 = tight junction protein 1.
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Humankind has existed in some form for about 2.5 million
years, but it is only in the last 10,000 years that it has been
exposed to wheat. During the 20th century, nutritional needs
increased dramatically due to the food shortage cause by the 2
subsequent World Wars in the first half of the century and the
exponential growth of the world population in the second half of
the century. In this context, the main effort of many agronomists
and geneticists was to create new wheat varieties that are stronger
and richer in gluten content [1–3]. In 1941, the Nutrition Soci-
ety, a group of researchers interested in nutritional problems,
considered the need to increase wheat production and expand
the global wheat output by 5-fold by the end of the 20th century.
It is very probable that new kinds of wheat, particularly enriched
in gluten content, have greatly contributed to the explosion of
gluten-related diseases, although no data in the literature actu-
ally confirm this hypothesis. Increased wheat production may
have had an effect on celiac disease (CD) prevalence, which was
reported in the UK in 1950 as 1:8000 inhabitants and increased
to about 1% of the general population in recent decades [4–8].
The recent rise of the market for gluten-free products in the
United States, influenced in part by advertising campaigns that
claim a medical need for a gluten-free diet (GFD), largely ex-
ceeds the foreseeable consumption of the CD patient population.
This is just one of the factors that raise questions about possi-
ble gluten reactions apart from CD and wheat allergy (WA). A
consistent although undefined percentage of the general popula-
tion consider themselves to be suffering from problems caused
by wheat and/or gluten ingestion, even if they do not have CD,
because they test negative for CD serology and histopathol-
ogy. Similarly, these people have no evidence of positive im-
munoglobulin E (IgE)-mediated assay documenting WA; never-
theless, they exclude wheat and gluten from their diets. In most
cases, this happens because of negative experiences reported af-
ter eating wheat-containing foods and the benefits derived from
a GFD [9–11].
Furthermore, this suggests that the general population has
adopted this point of view, relying on self-diagnosis (“hyper-
sensitivity to wheat and gluten”) and subsequent therapy (i.e.,
GFD) far more readily than the medical/scientific community.
This can be seen by a 4598:1 ratio of Google to PubMed
citations for the keywords “non-celiac gluten sensitivity,” as
well as several papers expressing clear skepticism or simple
caution [12].
The nonmedical specialist press has suggested that “17 mil-
lion Americans are gluten sensitive.” It must be remembered that
this is a “big business,” with a projected increase in the market
for gluten free products from $100 million in 2003, $1.31 billion
by 2011, to $1.68 billion by 2015 [13].
Most of these patients report a long clinical history, mainly
characterized by gastrointestinal symptoms (abdominal pain and
tenderness, irregular bowel habits: constipation or diarrhea or
alternating bowel movements); very often they consult a num-
ber of physicians, seeking to reach a CD diagnosis but they
are considered simply suffering from irritable bowel syndrome
(IBS). This unfortunate way of searching for medical help was
described by Elena Verdu` and colleagues in a clinical review
published in 2009 in the American Journal of Gastroenterology
[14]. This paper had the great value of stimulating the gas-
troenterology research community to carry out a number of new
studies on non-celiac gluten sensitivity (NCGS) and to consider
gluten sensitivity as a “fertile crescent” for research [15].
Here we review the international literature about this “new”
disease, consulting PubMed and Medline, using the search terms
“wheat (hyper)sensitivity,” “wheat allergy,” “wheat intolerance,”
“gluten (hyper)sensitivity,” and “gluten intolerance;” and we
discuss current knowledge about NCGS, seeking to define its
current pathogenic, clinical, and diagnostic criteria to provide a
practical point of view that might be useful to evaluate, diagnose,
and manage NCGS patients.
WHEAT AND GLUTEN: WHAT ARE THEY?
Gluten is the term used to identify the protein mixture of
glutelins and gliadins (prolamines), which occurs in the en-
dosperm of wheat and other cereals (such as barley, rye, and
spelt) and can be fractionated to produce alpha, beta, and gamma
peptides. The ratio of glutelins to gliadins in the protein mixture
is approximately 1:1. Gliadins, a group of proteins that are rich
in proline and glutamine, have been identified as the main gluten
component that is toxic for CD patients [16–18].
Nowadays, gluten is one of the principal dietary components
for most of the global population, particularly in Europe and
the United States. Mean daily gluten ingestion is 10–20 g in the
Mediterranean area and even higher in other populations [19,20].
New variants of wheat have arisen as a result of agricultural
mechanization and the growing industrial use of pesticides and
fertilizers, which could have a leading role in the adverse im-
munologic reactions to gluten. Moreover, the process of bread
leavening has been progressively shortened, resulting in an in-
creased concentration of toxic gluten peptides in bakery prod-




Currently NCGS is mainly defined by negative criteria. We
talk about NCGS when CD serology is negative, duodenal his-
tology is negative, and IgE-based assays (prick tests or serum-
specific IgE dosage) are negative. The only positive requirement
to diagnose NCGS is the presence of troubles caused by wheat
ingestion and their disappearance on gluten-free/wheat-free diet.
In other words, we consider an NCGS diagnosis in all cases that

























Table 1. Gluten Sensitivity Diagnosis Criteria
Diagnotics Tools Celiac Disease Gluten Sensitivity
Celiac disease serology:
Antitissue transglutaminase Positive Negative
Antigliadins antibodies Positive Positive (50% of the cases)
Anti-endomysial antibodies Positive Negative
Deaminated gliadin peptide antibodies Positive Negative
Duodenal histology (Marsh-Oberhu¨ber classification) Positive (Marsh 1–3) Negative (Marsh 0–1)
HLA haplotypes (DQ2-DQ8) Present Absent/present
IgE-based assays (prick tests or serum-specific IgE dosage) Negative Negative
Clinical features Troubles caused by wheat ingestion and
their disappearance on gluten-free diet
Troubles caused by wheat ingestion and
their disappearance on
gluten-free/wheat-free diet
HLA = human leukocyte antigen, Ig = immunoglobulins.
lack the key CD criteria (presence of antitissue transglutaminase
[anti-tTG] antibodies and endoscopic or histologically signifi-
cant enteropathy; i.e., Marsh 3) and do not satisfy the criteria
for IgE-mediated wheat allergy but respond to gluten exclusion
(Table 1) [9,10,23–27]. NCGS is frequently perceived by the pa-
tients themselves and they consult physicians seeking to reach a
definite diagnosis of CD, or at least of “wheat hypersensitivity,”
but as aforesaid this is generally opposed, because the patients
do not fulfill CD diagnostic criteria and do not show laboratory
assays documenting an IgE-mediated food allergy. On the other
hand, the role of emotion is known to be pivotal in these patients.
Consequently, a clinical response to elimination diet and the use
of double-blind placebo-controlled challenge (DBPCC) to con-
firm NCGS diagnosis are recommended, even though DBPCC
is quite cumbersome and time consuming and therefore very
rarely employed. For many years, these patients continued to
consume gluten-containing foods because gluten was not con-
sidered to be the cause of their symptoms. As a result, they
were left in a no man’s land, unrecognized by either allergists
or gastroenterologists. Much like patients who had IBS, NCGS
patients were commonly referred to psychiatrists because they
were believed to have an underlying mental illness as a result of
the poor physician awareness of this disease [9,23–27].
In 2011 an international panel of experts from 14 coun-
tries participated in a consensus meeting in London and de-
fined NCGS as “a non-allergic and non-autoimmune condition
in which the consumption of gluten can lead to symptoms sim-
ilar to those seen in CD.” The consensus statement suggested
that clinical symptoms can overlap with CD or WA, respond to
GFD, and worsen on gluten reintroduction, but patients must
be characterized by negative CD-specific antibodies (absence
of anti-tTG antibodies, anti-endomysial antibodies [EMA], or
deaminated gliadin peptide [DGP] antibodies) and normal duo-
denal histology, even if an increased density of CD3+ IELs
could be detected, as reported by Sapone et al. [23]. In summary,
the hallmarks for NCGS diagnosis are clinical improvement on
a GFD in the absence of anti-tTG, EMA, or DGP antibodies and
intestinal mucosal abnormalities [23].
The concept of NCGS has challenged physicians and investi-
gators over the years. Data published in 1980 and 2000 suggested
the actual existence of a syndrome caused by the ingestion of
gluten in a subset of patients who did not have CD or WA, even
though it has been suggested that some of these patients might
be affected from “potential CD” [28,29].
However, most published descriptions of this potential dis-
ease involve patients with positive serology, associated with in-
traepithelial lymphocytosis in the duodenum (Marsh-Oberhu¨ber
modified classification 0–1). In other words, they may just be
CD patients not fulfilling the classic diagnostic criteria. There-
fore, we had to check the existing literature to carefully se-
lect available works, considering only those closely meeting the
above-mentioned NCGS criteria [27,30].
PATHOGENESIS OF CD, WA, AND NCGS
The role of gluten in CD is clear. Toxic peptide sequences
have been determined, genetic susceptibility loci have been iden-
tified, and pathological processes are fairly well known. Deami-
dation of gliadin epitopes by tTG enables them to be presented
with a high affinity, in genetically susceptible individuals, to
major histocompatibility complex class II (MHC-II) T-cells.
This process initiates a series of events, resulting in mucosal
inflammation, small intestinal villous atrophy, increased intesti-
nal permeability, macro- and micronutrient malabsorption, and
resultant CD complications. The disease is an autoimmune dis-
order, as heralded by the demonstration of specific serologic
markers, most notably serum anti-tTG antibodies, autoimmune
enteropathy, and autoimmune comorbidities (e.g., autoimmune
thyroiditis, type-1 diabetes, etc.) [31–33].
In WA, immunoglobulin E (IgE), cross-linking by repeated
sequences in gluten peptides (for example, Ser-Gln-Gln-Gln-
(Gln-)Pro-Pro-Phe), triggers the release of chemical mediators,
such as histamine, from basophils and mast cells [34,35].
On the contrary, NCGS pathogenesis is still largely unde-
termined. A preliminary key issue is whether symptoms are

























Fig. 1. Damage and abnormalities in epithelial cells induced by wheat through nonimmunomediated mechanisms.
being induced by peptide(s) derived from gliadin proteins or by
nongliadin gluten parts, or by gluten contaminants, or by other
wheat constituents, such as more protein (e.g., wheat amylase–
trypsin inhibitor) or carbohydrates. Broad in vitro evidence,
both in celiac and non-celiac experimental models, points out
how gluten and gliadin might directly cause damage and ab-
normalities in epithelial cells by nonimmunomediated mecha-
nisms (Fig. 1). For example, gliadin is known to cause cellu-
lar cytoskeleton rearrangement, through the zonulin pathway,
and loss of tight junctions, modifying protein expression, which
results in a paracellular permeability increase of the small in-
testine mucosa [36–41]. Moreover, gliadin has a toxic effect
because it reduces small intestinal mucosal cell F-actin content,
inhibits RNA and DNA synthesis, inhibits epithelial cell growth,
increases oxidative stress, and induces apoptosis, thereby alter-
ing mucosal homeostasis [42–46]. Alternatively, gluten might
cause gastrointestinal neuromuscular abnormalities by increased
acetylcholine release from the myenteric plexus and consequent
cholinergic activation, as indicated by experimental models in
DQ8-restricted mice. This might lead to an increase in smooth
muscle contractility, and indirectly luminal water content rise,
due to epithelial prosecretory state, a neuromediated effect.
Clearly, other wheat antigens may act in a similar way, too.
Symptoms might also be induced by enteric nervous system
stimulation both directly, by neuroactive molecule supply, and
by indirect release of neurotransmitters from, for example, mast
cell activation. Neural active peptides from gluten or wheat in-
gestion might potentially gain access to enteric nerve endings,
but these are still unknown and their absorption might seem less
likely, given normal intestinal permeability in NCGS patients
(see section labeled “Intestinal Mucosa Epithelial Barrier Func-
tion”). Newer techniques, such as examining basophil activation
in response to gluten or wheat stimulation, might suggest other
pathological mechanisms for gluten-related symptoms [47–49].
In accordance with the above-mentioned gluten effect on gas-
trointestinal neuromuscular function in experimental models,
it is quite frequent in clinical practice to examine CD patients
showing gastrointestinal motor abnormalities, similar to those of
IBS. In fact, in 30%–60% of patients, physical examination and
dyspeptic/dysmotility symptoms (epigastric discomfort, early
satiety, etc.) suggest a gastrointestinal motility disorder [50].
Consistent data are now available on the presence of disturbed
motility of the esophagus, stomach, small intestine, gallblad-
der, and colon of untreated celiac patients. However, gastroin-
testinal abnormalities differ in various gastrointestinal locations:
esophageal transit, gastric and gallbladder emptying, and oro-
cecal transit time are delayed, and small bowel and colonic
transit is faster. Motility disorders of the gut in CD patients are
also a predisposing factor in the development of small intesti-
nal bacterial overgrowth and may contribute both to the devel-
opment of symptoms in some untreated CD patients and to a
persistence of symptoms after gluten-free diet in some other CD

























patients. Therefore, surveillance for CD in patients complain-
ing of dysmotility-like dyspeptic symptoms or IBS should be
increased [50–57]. In this context, it has been demonstrated that
small bowel and/or colonic transit is speeded up in 46% of pa-
tients with diarrhea-predominant IBS. Improvement in these pa-
tients with gluten withdrawal is associated with HLA-DQ2/DQ8
positivity. Patients positive for HLA-DQ2 and HLA-DQ8 had
faster small bowel and/or colonic transit compared to HLA-
DQ2-negative and HLA-DQ8-negative patients. In contrast, gas-
tric emptying seems not to be associated with HLA-DQ2 and
HLA-DQ8 status [58]. However, HLA-DQ2/DQ8 expression in
these patients might be markers of potential CD in a subgroup
of IBS patients, who consequently appear to take advantages
of a gluten-free diet [59]. Therefore, it is possible to speculate
that gluten-/gliadin-induced gastrointestinal motility abnormal-
ities might also be involved in NCGS patients, as demonstrated
in experimental models and in CD patients, and be responsible,
at least in part, for some of NCGS patient symptoms. Carbohy-
drates, among nongliadin and nongluten components of wheat,
may also be considered a likely candidate, especially fructans
and other fermentable oligo- and di-monosaccharides and poly-
ols, because they are poorly absorbed in the small intestine and
may induce fermentation and functional gut symptoms [60].
Therefore, symptom induction might be a wheat-specific rather
than a gluten-specific phenomenon, so the term NCGS should
possibly be replaced by wheat sensitivity. Finally, other lumi-
nal antigens, such as drugs or intestinal microbial components
(dysbacteriosis), might contribute to enhanced inflammatory re-
sponses to dietary antigens such as gluten or wheat [61,62].
THE TWO SIDES OF NCGS
IMMUNOPATHOLOGY AND
INTESTINAL BARRIER FUNCTION
Researchers evaluated NCGS pathology considering 2 dif-
ferent sides of the problem: the possible role of innate versus
adaptive immunity and the intestinal mucosa epithelial barrier
function (Table 2 and Fig. 2).
Innate Versus Adaptive Immunity
Acquired data indicate that NCGS is not related to the ge-
netic pattern found in most patients with CD. Though CD is
characterized by a strong genetic association with the MHC-II
haplotype (about 95% of patients carrying HLA-DQ2, and the
remaining 5% carrying HLA-DQ8), only about 50% of patients
with NCGS carry HLA-DQ2 and/or HLA-DQ8, a percentage
slightly higher than the general population (30%); all of these
data suggest a reduced involvement of MHC-dependent adaptive
immune response in NCGS compared to CD. In addition, serol-
ogy for common CD auto-antibodies (e.g., anti-tTG) is negative
[63–65]. NCGS mucosa contain increased numbers of CD3+ T-
cells and T-cell receptor-alpha/beta intraepithelial lymphocytes
(IELs) compared to controls but lower than those in active CD
Table 2. Celiac Disease, Gluten Sensitivity, and Food Allergy Immunologic and Intestinal Epithelial Barrier Function Findings
Immunologic and Intestinal Epithelial
Barrier Features Celiac Disease Gluten Sensitivity Food Allergy
HLA-DQ2/DQ8 Present Present (lower than CD)/absent Present/absent
CD3+ intraepithelial lymphocytes Increased Increased (lower than CD) Normal
TCR-alpha/beta IELs Increased Increased (lower than CD) Normal
TCR-gamma/delta IELs Increased Normal Increased
TH1 and TH17 clones expansion and
cytokines production (e.g.,
IFN-gamma, IL-6, IL-17A, and IL-21)
Increased Normal Increased (in addition to TH2
clone expansion and
cytokines production)
T regulation (Treg) clones expansion and
cytokines/messengers production
(e.g., FoxP3, TGF-beta 1, TGF-β1,
and IL-10)
Increased/reduced Reduced Increased/reduced
TLRs expression Increased TLR4 and TLR9
expression (but not of TLR3 and
TLR7), and reduced TLR2
expression
Increased TLR2 expression
and to a lesser extent of
TLR1 (but not of TLR4)
Reduced TLR2 and TLR4
expression
Intestinal mucosal permeability
(assessed by lactulose–mannitol test)
Increased Reduced Increased
Tight junction protein expressions:
CLDN4 Normal Increased NA
CLDN1 Normal Normal Increased
CLDN2 Normal Normal NA
OCLN Normal Normal Increased
TJP-1 Normal Normal Increased
CD = celiac disease, TCR = T-cell receptor, IEL = intraepithelial lymphocytes, IFN = interferon, IL = interleukin, TGF = transforming growth factor, TLR = toll-like
receptor, HLA = human leukocyte antigen, CLDN = claudin, OCLN = occludin, TJP-1 = tight junction protein 1.

























Fig. 2. Innate and adaptive immunity response to wheat.
patients and in the context of a relatively conserved villous ar-
chitecture (0 and 1 stages of the Marsh-Oberhu¨ber modified
classification). Numbers of T-cell receptor-gamma/delta IELs
(killing phenotype) were elevated only in CD patients, whereas
NCGS patients were similar to controls. This is consistent with
a more limited involvement of the adaptive immune system in
NCGS compared to CD and may also explain why this condi-
tion seems not to be accompanied by significant autoimmune
phenomena [63,64].
CD has been considered a classical TH1-mediated disorder
because of the enhanced mucosal mRNA expression of inter-
feron (IFN)-gamma, but not of interleukin (IL)-4, in patients
with untreated disease. Following the identification of the TH17
T cell subset (interleukin [IL]-17-producing CD4+ T helper
cells), and the growing evidence that these cells are centrally
involved in the pathogenesis of autoimmune disorders, such as
collagen-induced arthritis and colitis, it has become important
to investigate the possible involvement of TH17 cells in CD.
TH17-associated cytokines expression—for example, IL-17A—
is higher in patients with active CD as opposed to patients on
a GFD. In addition, it has been demonstrated that gliadin can
induce TH17-polarizing cytokines—for example, IL-1beta and
IL-23 production in peripheral blood monocytes—providing a
possible causative link between gluten exposure and TH17 cell
expansion in CD. Unlike NCGS patients, CD patients show in-
creased levels of adaptive immune markers in the small intesti-
nal mucosa, triggered by DQ2 DQ8-bounded tTG-deamidated
gluten peptides and associated with TH1 and TH17 clone activa-
tion and TH1- and TH17-associated cytokine production, includ-
ing IFN-gamma, IL-17A, IL-6 (pleiotropic cytokine promoting
differentiation and function of TH17 cells), and IL-21 (also re-
lated to TH1 and TH17 cell pathology) [63–69].
Another interesting immunological finding that might distin-
guish NCGS from CD concerns mucosal expression of genes
associated with T-regulation (Treg) cells. In CD and CD-related
autoimmune diseases a resistance of effector T lymphocytes to
suppression by adaptive Treg cells has been demonstrated and
has been proposed to explain the loss of immune homeosta-
sis and development of autoimmune responses. Although per-
centages of CD4+ CD25+ FoxP3 + intraepithelial and lamina
propria lymphocytes were significantly higher in patients with
active CD compared to healthy controls, proliferation and IFN-
γ production of intestinal T lymphocytes were significantly less
inhibited by autologous or heterologous Treg cells in CD pa-
tients than in controls [70]. Several Treg cells have been found
to be important for oral food tolerance: TH3 cells, a popula-
tion of CD4+ cells that produce transforming growth factor–
beta (TGF-β); T regulatory type 1 (Tr1) cells, which secrete
IL-10; CD4+ CD25+ regulatory T-cells, which express the
transcription factor forkhead/winged-helix transcription factor
box protein 3 (FoxP3); CD8+ suppressor T-cells; and gamma-
delta T-cells. Natural Treg cells are CD4+ CD25+ T-cells that
develop and migrate from the thymus to perform their key
role in immune homeostasis, whereas adaptive Treg cells are

























nonregulatory CD4+ T-cells that acquire CD25 (IL-2R alpha)
expression outside of the thymus and are typically induced by
inflammation and disease processes, such as autoimmunity and
cancer [71]. Considering the lack of association between NCGS
and autoimmune serology and/or diseases, it is possible to as-
sume that adaptive Treg cells efficiently prevent progression to
this kind of response in NCGS patients. Surprisingly, expres-
sion of FoxP3 was found to be reduced in patients with NCGS
compared to CD, perhaps in the context of a generally reduced
activation of adaptive immunity in NCGS relative to CD patients
[63]. However, the overall expression of this and other messen-
gers (e.g., TGF-β1, and IL-10) represents a rather controversial
aspect of CD autoimmunity, because both downregulation and
upregulation of FoxP3 and other Treg-dependent molecules have
been reported in patients with CD and related autoimmune con-
ditions (e.g., type 1 diabetes mellitus) [72–76].
Among innate immune mechanisms, toll-like receptors
(TLRs) represent a family of evolutionarily conserved recep-
tors able to detect microbial invasion via pattern recognition and
to mediate a rapid inflammatory response, inducing type I in-
terferon and other cytokines, which may or may not progress
into an antigen-dependent adaptive response. The expression of
TLR2 (and to a lesser extent TLR1 but not TLR4) is consider-
ably higher in the intestinal mucosa of NCGS patients compared
to CD patients, confirming a prevalent role of the innate immune
system in the pathogenesis of NCGS [63]. However, innate im-
munity and TLR expression and function are also important in
CD pathogenesis. TLR4 expression levels (but not TLR3 and
TLR7) on duodenal biopsies are higher in CD specimens com-
pared to controls. CD patients with high TLR4 levels also show
high levels of interleukins (IL-1, IL-6, IL-8, and IL-17) as well as
transcription factors (IRAK4, MyD88, and NF-κB) [77,78]. In
another study, TLR2 mRNA expression was significantly lower
in untreated and treated celiac patients, whereas TLR9 mRNA
expression was higher in untreated celiac patients compared to
controls [79].
Taken together, these preliminary data seem to suggest that
innate rather than adaptive immunity has a prominent pathogenic
role in NCGS. The main involvement of innate versus adaptive
immune pathways might help explain the clinical and serolog-
ical differences that can be seen in CD versus NCGS patients.
However, it must be considered that there are only a few stud-
ies available, mainly on experimental models, with a possible
bias in NCGS patient selection (e.g., overlap with CD), due to
the lack of clearly defined NCGS diagnostic criteria. Therefore,
other pathogenic mechanisms might be supposed; for exam-
ple, not IgE-mediated allergic mechanisms (see section labeled
“Non-Celiac Gluten Sensitivity or Gluten Allergy?”).
Intestinal Mucosa Epithelial Barrier Function
Small intestine mucosa epithelial barrier modifications rep-
resent another possible factor involved in the pathogenesis of
gluten-related disorders; that is, CD and NCGS. Loss of intesti-
nal barrier function, which has been clearly established in CD,
represents a key mechanism for autoimmunity development, by
the continuous and aberrant passage of antigens through in-
testinal epithelium. This may cause an immunity switch from
tolerance to response, hence representing an increased risk for
autoimmune diseases in subjects with particular genetic deter-
minants, both MHC and non-MHC, conditioning inappropriate
antigen processing and presentation [80–82]. However, patients
with NCGS, unlike CD, did not show changes (or show re-
duction) in intestinal mucosa permeability, as assessed by the
lactulose–mannitol test. In particular, Sapone et al. demonstrated
an increased lactulose-to-mannitol urinary ratio, indicating en-
hanced permeability of the small intestine, in patients with CD
but not in NCGS [63]. In addition, Biesiekierski et al., using a
dual sugar absorption test (i.e., cellobiose/mannitol sugar per-
meability test), did not find any significant difference in the in-
testinal barrier function of 2 randomly treated groups of NCGS
patients, one challenged by gluten and the other by placebo [83].
In the intestinal epithelium, paracellular permeability is reg-
ulated by intercellular tight junctions (TJs) and multiple pro-
teins forming cTJs strands (e.g., occludin [OCLN], claudins
[CLDNs], and zonula occludens-1 protein, also known as tight
junction protein 1 [TJP-1]). TJs have a critical role in the de-
velopment of intestinal immunological responses. When TJs’
integrity is compromised, an immune response to environmen-
tal antigens, which might cross-react with host antigens, may
develop, thereby triggering CD onset [40,84,85]. In particular,
CLDNs are integral TJ components, critical for maintaining
cell–cell adhesion in epithelial monolayers. The overall bal-
ance of CLDN species, expressed in a specific cell type, de-
termine the permeability of its TJs. For instance, CLDN1 and
CLDN4 are postulated to decrease TJ-dependent permeability,
whereas CLDN2 is postulated to increase TJ-dependent perme-
ability [86]. As recently pointed out, in duodenal biopsy samples
from NCGS patients, TJs component polymerase chain reaction
analysis showed a notably higher expression of CLDN4 mRNA
compared to CD patients. This finding suggests that the former
might have a less permeable mucosa than the latter. Other CLDN
genes (e.g., CLDN1 and CLDN2) as well as other genes associ-
ated with TJ function (i.e., OCLN and TJP-1) did not appear to
be expressed differently in NCGS and CD mucosa [63].
NON-CELIAC GLUTEN SENSITIVITY
OR GLUTEN ALLERGY?
In a recent study, we demonstrated that a high-frequency
characteristic of NCGS patients is the coexistence of multiple
food intolerance, including cow’s milk, egg, and other foods. In
this way, we suggested the existence of at least 2 distinct groups
of NCGS patients: the first characterized by NCGS patients
alone and the other by patients intolerant to wheat, cow’s milk

























protein, and many other foods (multiple foods hypersensitivity,
including NCGS). Patients showing multiple food hypersensi-
tivity presented characteristics more similar to allergy rather
than to CD, although none of them tested positive for IgE-based
assays. In accordance with an allergy hypothesis, these patients
showed a higher frequency of family and personal history of
food allergy, especially in infancy, and coexistent atopy than
the other group. Their predominant presence in the study group
probably conditioned the results of the immunology assays (ba-
sophil activation assay, IgG antigliadin antibodies [AGA] and
anti-betalactoglobulin positivity) and of the histology studies
(mucosal eosinophil infiltration in the duodenum and colon).
Therefore, it is possible to hypothesize an allergic, not IgE-
mediated, pathogenesis in the development and presentation of
gluten sensitivity abnormalities and symptoms [87].
Available data do not seem to support this point of view,
but they refer especially to IgE-mediated experimental patient
surveys. Patients with untreated food allergy express equal den-
sities of total intraepithelial CD3+ and alpha/beta + T-cells
but significantly higher densities of gamma/delta + cells and
gamma/delta + /CD3+ ratio than patients currently on an elim-
ination diet for food allergy or healthy controls [88–90].
In the context of food allergy, in contrast to NCGS, where
no TH1 and/or TH17 clone expansion and/or cytokine produc-
tion have been demonstrated, it has been shown, especially in
experimental models (mice), that not only TH2 cytokines (IL-5,
IL-13, and IL-10) but also TH1 cytokines—for example, IFN-
gamma—and TH17 cytokines—for example, IL-17—are pro-
duced. Interestingly, TH17 cells and their associated cytokines
(the IL-17 family, IL-21, IL-22, and IL-23) have paradoxical
effects at the intestinal level, because they display both protec-
tive/homeostatic and pathogenic/inflammatory functions. How-
ever, functional studies provided evidence for the different roles
of IL-17A and IL-17E in the regulation of immune responses: IL-
17A is involved in inflammation, and IL-17E is able to induce
TH2 cytokine production and eosinophilia. Therefore, IL-17E
but not IL-17A is associated with allergic sensitization [91–94].
Similarly to CD, data about FoxP3 expression and food al-
lergy are quite contradictory. Like NCGS patients, children with
food allergy show statistically significant lower levels of the
FoxP3 and IL-10 gene expression than healthy children. Those
acquiring tolerance to the food show significantly higher levels
of the FoxP3 gene expression than children with active food
allergy [95]. However, whereas some studies showed normal
FoxP3 levels in infants with milk and egg allergy, some others
demonstrated FoxP3 + cells increasing in the duodenum of pa-
tients with untreated food allergy, even if these cells are not able
to suppress the harmful immune response, indicated by the low
FoxP3 transcript expression [96–98].
Moreover, other studies showed that food allergy mecha-
nisms are more similar to those of CD than those reported in
NCGS. In contrast to NCGS, but similar to CD, recent studies
indicated that TLR polymorphisms or their impaired signaling,
specifically TLR-2 and TLR-4, were correlated with a higher
risk for food allergy, through effects on innate immune path-
ways, even if other ones did not demonstrate such a correlation.
TLR2- and TLR4-dependent signals, provided by the intestinal
commensal flora, inhibit TH2-mediated allergic response devel-
opment to food antigens, by antigenic stimulation of the gut as-
sociated lymphoid tissue (GALT), modification of lymphocyte
responsiveness, and generation of TH1-based memory effectors
[96,99–101].
In contrast to NCGS, but similarly to CD, impaired intestinal
permeability, evaluated by lactulose–mannitol ratio urinary de-
tection, can also be detected in patients with adverse reactions
to food, including food allergy. A statistically significant asso-
ciation has been demonstrated between the severity of referred
clinical symptoms and the increase in the intestinal permeability
index [102,103]. In patients with cow’s milk allergy or intol-
erance, cellobiose/mannitol sugar permeability test, performed
before and after cow’s milk challenge, showed alteration of in-
testinal permeability induced by milk, suggesting the usefulness
of the sugar permeability test, in addition to clinical observa-
tion, as an aid in the evaluation of challenge tests in infants with
suspected cow’s milk allergy or intolerance [104,105].
A relationship between intestinal TJ protein expression and
food allergy has been evaluated in a single study, demonstrating
that exposure of small intestinal biopsy specimens of patients
with food allergy to food allergens led to a significant increase
in IgE-positive cells with an enhanced histamine and tryptase re-
lease and an altered expression of tight junction proteins—for ex-
ample, CLDN1, OCLN, and TJP-1—in contrast to NCGS, where
they are normally expressed. To date, no data are available re-
garding other CLDNs; for example, CLDN2 and CLDN4 [106].
CLINICAL CHARACTERISTICS OF
NCGS
NCGS epidemiology is far from established. NCGS preva-
lence was reported to be about 6% based on the Maryland clinic
experience (where between 2004 and 2010, 5896 patients were
evaluated and 347 fulfilled NCGS diagnostic criteria), even
though these data could overestimate the real prevalence of
the disease, having been recorded in a referral center [23,64].
Furthermore, a recent paper, summarizing the results from the
continuous National Health and Nutrition Examination Survey
(years 2009–2010), reported a possible prevalence of NCGS of
0.55% in the general population in the United States [107]. It is
possible that the real prevalence of NCGS is intermediate in this
range (0.55%–6%).
It has been reported that NCGS onset is at a median age
of 40 years; however, our recent study, including the largest
series of NCGS patients, showed a median age of 28 years, thus
suggesting that NCGS affects patients younger than previously
reported, and functional bowel disorders (including IBS) are

























more prevalent in females than in males (male-to-female ratio
ranging between 1:2.5 and 1:4) [25,87].
NCGS is clinically characterized by symptoms/signs that
usually occur soon after gluten ingestion, improving or disap-
pearing (within hours or a few days) with gluten withdrawal
and relapsing following its reintroduction. Clinical presentation
of NCGS is a combination of IBS-like symptoms (e.g., bloat-
ing, abdominal pain, bowel habit abnormalities [either diarrhea
and/or constipation]), and systemic manifestations (e.g., foggy
mind, headache, fatigue, depression, joint and muscle pain, leg
or arm numbness, dermatitis [eczema or skin rash], and anemia)
[9,10,23–25,87]. Biesiekierski et al., in a double-blind random-
ized placebo-controlled trial, conducted on patients with IBS in
whom CD was excluded and who were symptomatically con-
trolled on a GFD, proved that IBS-like symptoms and tiredness
reoccurred more frequently in the gluten-challenged group than
in the placebo group (68% and 40%, respectively), thus sug-
gesting a link between gluten assumption and symptom origin
[83]. Although the frequency of intestinal IBS-like symptoms
is higher than extraintestinal manifestations, all patients usually
report 2 or more extraintestinal symptoms, the most common
being foggy mind (42%), defined as a sensation of lethargy that
occurs after eating gluten-containing foods, and fatigue (36%)
[65]. However, the authors reported that only one extraintestinal
manifestation (tiredness) was associated with IBS-like symp-
toms [83]. Thus, other data are needed to establish the actual
prevalence and type of extraintestinal symptoms in NCGS pa-
tients.
Brottveit et al.[108] considered the presence of somatization,
personality traits, anxiety, depression, and health-related quality
of life in NCGS patients compared to CD patients and healthy
controls and compared the response to gluten challenge in the
former and the latter. NCGS patients did not exhibit any tendency
for general somatization. Personality and quality of life did not
differ between NCGS and CD patients and were mostly at the
same level as in healthy controls. NCGS patients reported more
abdominal and nonabdominal symptoms than CD patients after
gluten challenge [109].
Unlike CD patients, NCGS patients do not seem to have
autoimmune comorbidities. In a group of 78 NCGS patients,
none had type 1 diabetes mellitus and only one (1.3%) had
autoimmune thyroiditis, compared to 5% and 19%, respectively,
of 80 CD patients [65].
Recently we retrospectively reviewed the characteristics of
a large group of IBS-like patients, fulfilling the newly proposed
NCGS criteria, and showed that a considerable percentage (one
fourth) of these patients who underwent DBPCC wheat chal-
lenge, were actually suffering from NCGS. The study showed
how food allergy history in infancy, coexistent atopic diseases,
weight loss, and anemia were more frequent in NCGS patients
than in IBS controls. We suggested that weight loss and anemia
might be due, at least in part, to the self-restricted diet started
by the patients, which usually excluded many foods. A high-
frequency NCGS patient characteristic was the coexistence of
multiple food intolerance, including cow’s milk, egg, and other
foods. In this way, we suggested the existence of at least 2 distinct
groups of NCGS patients (Fig. 3): one characterized by NCGS
alone and the other by patients intolerant to wheat, cow’s milk
protein, and many other foods (multiple food hypersensitivity,
including NCGS). Patients belonging to the first group showed a
higher frequency of HLA-DQ2 or -DQ8 haplotype; furthermore,
duodenal lymphocytosis was shown in 94% of cases, and EMA
assay in the culture medium of duodenal biopsies tested positive
in one third of them. Considering that symptomatic patients, who
produce EMA in the duodenal culture, can subsequently develop
villous atrophy when remaining on a gluten-containing diet, it is
possible to hypothesize that a percentage of these patients could
be predisposed to develop villous atrophy in the future. The
second group (multiple food hypersensitivity, including NCGS)
presented with characteristics more similar to allergy rather than
CD patients, although none of them tested positive for IgE-based
assays. These patients showed a higher frequency of personal
history of food allergy in infancy and coexistent atopy than the
other group [87,110,111].
DIAGNOSTIC APPROACH TO NCGS
Although CD and NCGS seem to be 2 different conditions,
it has been reported that 10 of 78 (12.8%) patients with NCGS
were first-degree relatives of CD patients [65]. Furthermore, it
is known that local in-rectum gluten instillation can be a useful
test to identify mucosal evidence of NCGS at an early stage in
asymptomatic first-degree relatives of CD patients [112,113].
Both of the above-mentioned characteristics could be a link be-
tween NCGS and CD and could lead us to hypothesize that
a percentage of NCGS patients could represent the first initial
stage of CD. Consequently, the first step in evaluating patients
suffering from suspected NCGS is to distinguish between this
condition and a very early CD stage. In this regard, we suggest
the usefulness of the HLA haplotype determination to search for
the DQ2 or DQ8 forming alleles. In fact, due to the high negative
predictive value of the genetic assay, in the patients who will re-
sult negative for DQ2 and DQ8 haplotype, the CD diagnosis can
be excluded. For the patients carrying the DQ2 or the DQ8 hap-
lotypes, a successive useful approach is the anti-endomysium
assay (EmA assay) in the culture medium of duodenal biop-
sies [110,111]. In a group of NCGS patients we found subjects
with negative CD serology, normal small intestinal mucosa, but
positive detection of EMA in the culture medium of duodenal
biopsies [87]. Because a direct correlation between the serum
EMA titer and the severity of the intestinal histology damage
has been demonstrated [114], it is very probable that this sub-
group of NCGS patients really consisted of CD subjects in whom
positive serology and intestinal villi atrophy will develop in the

























Fig. 3. Distinct groups of NCGS patients.
future [110,111]. A similar progression has been demonstrated
in symptomatic patients showing positive serum EmA and nor-
mal villi architecture [115].
Elimination diet and open challenge (i.e., monitored rein-
troduction of gluten-containing foods) are often used to evalu-
ate whether the patient’s health improves with the elimination
or reduction of gluten from the diet and relapses after gluten
reintroduction. Gluten withdrawal is associated with a dramatic
improvement or even the disappearance of IBS-like and extrain-
testinal symptoms, and reintroducing gluten causes symptom re-
currence. Symptom discontinuance or reoccurrence, attributable
to the absence or presence of dietary gluten, should be consid-
ered a test indicating NCGS [9,10,23–25]. However, as afore-
said, because a placebo effect produced by gluten withdrawal
cannot be excluded, DBPCC studies are appropriate to confirm
NCGS diagnosis [87].
NCGS patients frequently report a personal history of food
allergy in infancy and coexistent atopy, so it is mandatory for
physicians to enquire about these topics. These characteristics
are more frequent in patients with multiple food hypersensitivity.
This subgroup of NCGS patients probably has a high frequency
of positive immunologic assays. In fact, about half of NCGS
patients had positive first-generation AGAs, especially of the
IgG class [87]. Although lower than in CD patients (80%–90%),
prevalence of IgG AGA in patients with NCGS is much higher
than in those with a variety of other gastrointestinal—for ex-
ample, IBS (20%) [116]—or nongastrointestinal diseases (e.g.,
connective tissue disorders and autoimmune liver disease, 9%
and 21.5%, respectively) or in the general population and healthy
blood donors (ranging from 2% to 8%) [117–122]. Therefore,
in the presence of clinical symptoms that suggest NCGS, IgG
AGA positivity, together with negative anti-tTG, EMA, and DGP
antibodies, NCGS diagnosis might be suspected.
More interestingly, an in vitro flow cytometric basophil ac-
tivation test with wheat (surface CD-63 expression) confirmed
a high sensitivity for NCGS diagnosis and seems to be, to date,
the most accurate NCGS marker [87,123].
Colon histology evaluation showed intraepithelial and lam-
ina propria eosinophil infiltration in about two thirds of cases;
this last finding was also frequently observed in the duodenum,
together with lymphocytosis. The diffuse ileum–colon involve-
ment could explain why the main symptoms in these patients
were lower (i.e., IBS-like ones) and not upper (i.e., dyspepsia-
like one) ones and define a histology pattern pointing to a NCGS
diagnosis [87].
Due to the lack of diagnostic tests for this condition, diag-
nosis is essentially made by exclusion (especially of CD and
wheat allergy). An intestinal biopsy sample should always be
obtained from patients with suspected NCGS when they are on
a gluten-containing diet to exclude the presence of villous atro-
phy, the hallmark of CD histopathology. About 60% of NCGS
patients have normal intestinal mucosa, with <25% IELs (grade

























Fig. 4. Diagnostic flowchart proposed for patients with suspected NCGS or CD.
Table 3. Future Research Field Throughout Gluten Sensitivity Hot Topics
Topic Possible Research Field
Pathogenetic role of peptide(s) derived from gliadin proteins or by
nongliadin gluten parts, or of gluten contaminants, or other wheat
constituent, either proteins (e.g., wheat amylase–trypsin inhibitor)
or carbohydrates
Double-blind placebo-controlled studies testing whole wheat in
comparison to its single component (gliadin, glutenin, gluten
contaminants, others wheat component) to asses actual patient
intolerance (gluten sensitivity or wheat sensitivity?)
Innate or adaptive immunologic mechanisms Evaluation of cytokines pattern in colon mucosa. Characterization of
T-cells and cytokines production; TH1 and TH17 clones expansion
and cytokines production, considering also TH2 clone and
TH2-related cytokines production; evaluation of eosinophils, mast
cells, macrophages, endothelial cell characteristics and
cytokines/mediators production
Toll-like receptor evaluation
Cholinergic activation, increased acetylcholine releasing from the
myenteric plexus, increased smooth muscle contractility, epithelial
prosecretory state, rise of luminal water content
Ultrasound evaluation of intestinal loop, before and after wheat/gluten
challenge
Search for serum markers of gluten sensitivity Performing in vitro flow cytometric basophil activation test with wheat
components and serum-specific immunoglobulin G assays for food
allergens to better explore the allergic gluten sensitivity hypothesis
Activation of hormonal responses to wheat/gluten exposure Evaluation of hormonal response; for example,
hypothalamic–pituitary–adrenal axis, renin–angiotensin system,
hypothalamic–pituitary–gonadal axis.

























0 according to the Marsh-Oberhu¨ber modified classification).
The remaining 40% of patients have a mild increase in IELs of
up to 40% (grade 1), which is lower than the IEL percentage
usually found in CD patients [11,63,65]. Nonetheless, grade 1
lesions are known to occur not only in gluten-related conditions
but also in a wide array of diseases; for example, food allergies,
common variable immunodeficiency, intestinal infections, He-
licobacter pylori infection, and autoimmune disorders (such as
Hashimoto thyroiditis and type 1 diabetes mellitus) [124–126].
In the context of a grade 1 lesion, EMA detection in the intestinal
mucosa culture medium would suggest a diagnosis of potential
CD rather than NCGS [110,111]. Finally, as recently suggested,
it might be useful to determine duodenal and/or ileum–colon
intraepithelial and lamina propria eosinophil counts, especially
when there is suspicion of allergic NCGS patients (i.e., with mul-
tiple food allergy, including NCGS) [87]. WA patients should
be excluded by skin prick testing and serum IgE antibodies spe-
cific to gluten and wheat fractions [127,128]. Figure 4 shows a
diagnostic flowchart for NCGS and CD.
NATURAL HISTORY, PROGNOSIS, AND
THERAPY OF NCGS
Knowledge about NCGS natural history and outcome is still
lacking. Whether patients with NCGS are at risk of complica-
tions, such as intestinal lymphoma or other gastrointestinal neo-
plasm, is yet to be determined. Similar to CD patients, NCGS
patients should change their dietary habits and consume foods
with minimal gluten content. Cereals, such as buckwheat, rice,
corn, and millet, and vegetables, such as quinoa, amaranth, and
soybean, are recommended as substitutes for gluten-containing
products. Commercially available gluten-free products used by
CD patients can be proposed to NCGS patients to achieve a thor-
oughly gluten-free regimen. Considering the lack of knowledge
as to whether NCGS is a permanent or a transient condition,
periodic reintroduction of gluten (yearly?) on GFD might be
advised [9,10,23–25].
CONCLUSIONS
Patients sensitive to dietary gluten are increasingly recog-
nized in daily clinical practice. As a result of the broad symp-
tom spectrum, NCGS might be regarded as a syndrome, rather
than a gastrointestinal disease. Indeed, IBS-like and extraintesti-
nal, mainly neurological, symptoms improve or disappear upon
gluten withdrawal and recur when gluten-containing foods are
reintroduced into the patient’s diet. To date it has been shown
that patients suffering from NCGS are a heterogeneous group,
composed of several subgroups each characterized by differ-
ent pathogenesis, clinical history, and probably clinical course.
NCGS diagnosis should be corroborated by CD and wheat al-
lergy exclusion, along with a personal history of food allergy
in infancy, coexistent atopy, and positive IgG AGA and flow
cytometric basophil activation test with wheat and duodenal
and/or ileum–colon intraepithelial and lamina propria eosinophil
counts. However, future research should aim to identify reliable
biomarkers for NCGS diagnosis and to better define the different
NCGS subgroups (Table 3).
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